Benzodiazepines: The Irreversible Neurological Damage Spain Normalizes

Benzodiazepines: The Cognitive Decline Normalized by Public Health

Benzodiazepine consumption in Spain reaches prescription levels considered reckless in other developed countries. A recent debate, antiestéticaturing over 300 interventions, has uncovered a silent cascade of testimonies and analyses pointing to a hidden problem: potentially irreversible neurological damage associated with chronic use of these anxiolytics.

In Germany, these drugs are dispensed only exceptionally; in Spain, they are prescribed like candy. The difference is not casual: while here their use for anxiety or insomnia is normalized, across the border, they have already been removed from the first line due to their risk profile. What explains this divergence? The answers are not optimistic.

More than 10 mg per day: the threshold of forgetting

The collected accounts describe a common pattern: pogre memory loss, brain fog, and concentration difficulties. One patient describes how he went from 10 mg daily of benzodiazepines to noticing permanent cognitive gaps, even after discontinuing the drug. Another claims he has lost 90% of his life memories, while a third compares his experience to the movie Memento: he did not remember whether he had turned off the stove or where he had left the keys.

The physiological explanation points to oxidative stress. Benzodiazepines alter the body's redox balance, reducing endogenous antioxidants and generating cellular damage that particularly affects the central nervous system. This is not a marginal theory: it is a documented mechanism that could explain why the decline persists even after withdrawal.

Antipsychotics and antidepressants: the combo that worsens damage

The debate is not limited to benzodiazepines. Many poly-medicated patients report that drug cocktails—quetiapine, olanzapine, topiramate—multiply adverse effects. Quetiapine, an atypical antipsychotic, is described as a drug that zombifies, destroys the liver and kidneys, and shortens life. Olanzapine is associated with dyslipidemia and type II diabetes, and is prescribed with the same lightness as an anxiolytic.

The feeling of having been victims of medical experimentation is recurrent. One participant recounts how he visited the psychiatrist with a specific problem and left with a diagnosis and prescription he never requested. From then on, each consultation added another drug, with no one questioning the previous treatment. The diagnostic label, once applied, is rarely removed.

To quit or not to quit: the trap of dependence

Addiction is another front. Benzodiazepines generate tolerance quickly: within a week, the initial dose stops working. Quitting can be hell. Those who manage it take years to recover—if they ever do—and many relapse. The alternative offered by conventional psychiatry is no better: antidepressants that erase memory and flatten emotions.

Faced with this crossroads, some seek alternatives such as melatonin, magnesium, or CBD, although results are mixed. Others opt for non-pharmacological rituals: exercise, contact with nature, music, or even religion. But the tacit consensus is that, once inside the chronic medication circuit, it is very difficult to get out.

The business of pharmacological unhappiness

Behind individual testimonies emerges a broader debate. Ted Kaczynski is cited—not for his ideology, but for his diagnosis of modern society: instead of eliminating the conditions that generate anxiety and depression, people are medicated to tolerate the intolerable. The pharmaceutical industry does not just sell pills; it sells chemical adaptation to a hostile environment.

There are no official figures on the number of people affected by irreversible neurological damage induced by psychotropic drugs. Nor does there seem to be a willingness to generate them. Meanwhile, the prescription remains the same: an anxiolytic, an antidepressant, another one. And the story of brain fog continues.